Pharmaceutical companies stop selling antihypertensive drugs with raw impurities from China – Chosunbiz

The Korea Food and Drug Administration (KFDA) discovered that N-nitrosodimethylamine (NDMA), which has the potential to act as a carcinogen in raw materials for the treatment of valsartan hypertension in Chinese,

This product contains 219 articles of treatment against valsartan hypertension which is distributed in Korea.

Recently, the European Medicines Agency (EMA) announced that the European Medicines Agency (EMA) was working on the use of drugs used for the treatment of hypertension. NDMA has been detected as an impurity in the raw material of valsartan produced by Zhejiang Huahai of China. NDMA is not a primary carcinogen, but it is likely to act as a carcinogen.

As a result, the drug manufacturer decided to discontinue imports of the product from the manufacturer and discontinue sales.

The agency said: "All drugs containing valsartan, which are now problematic, will be prescribed by the doctor and will be taken after the preparation of the pharmacy." "Currently, there is a warning of prohibition of prescription on the system" HARD ", which prevents the use and circulation of the patient."

Meanwhile, a medication for hypertension, which contains valsartan, Patients who take medication should report to the Korean Drug Safety Agency if there are any suspicious signs of detection of impurities.